4D Molecular Therapeutics, Inc. FDMT 深 沪
等待开盘 05-20 09:30:00 美东时间
8.405
+0.040
+0.48%
华盛通- 最 高8.645
- 今 开8.19
- 成交量 87.39万股
- 最 低 8.07
- 昨 收 8.365
- 总市值 4.39亿
- 52周最高 12.34
- 市盈率 静 --
- 换手率 1.67%
- 52周最低 3.55
- 委 比 -34.98%
- 总股本 5227.63万
- 历史最高 55.11
- 量 比 1.53
- 振 幅 6.87%
- 历史最低 2.235
- 每 手 1
- 风险率 2.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics granted 14 new non-executive employees 141,100 RSUs under its 2025 Employment Inducement Award Plan. The company is advancing innovative therapies with potential to transform treatment paradigms, including 4D-150 for retinal diseases and 4D-710 for cystic fibrosis. All product candidates are in clinical or preclinical development.
05-15 20:05
4D Molecular Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $3.047M Miss $5.167M Estimate
4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.99) by 2.02 percent. This is a 17.44 percent decrease over losses of $(0.86) per
05-08 04:34
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics reported Q1 2026 financial results, highlighting strong execution in wet AMD trials and upcoming milestones. Enrollment in 4FRONT-1 Phase 3 was completed ahead of schedule, with topline data expected in H1 2027. 4FRONT-2 enrollment is expected to complete in H2 2026, with data in H2 2027. 2-year PRISM and SPECTRA data are anticipated in Q3 and H2 2026, respectively. The company has $458 million in cash to support operati...
05-07 20:05
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan March 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ferguson Enterprises, Hartford Insurance Group and JP Morgan, on Monday. HIGHLIGHT
03-30 15:35
美股大行评级 | 小摩、瑞穗等下调阿里目标价最低至164美元；达登饭店、联邦快递、林肯教育服务、Planet Labs等获多家大行上调目标价
今日重点评级关注：瑞穗：维持RELMADA THERAPEUTICS"跑赢大市"评级，目标价从10美元升至19美元；奥本海默：维持Pelthos Therapeutics"跑赢大市"评级，目标价从60美元升至62美元
03-23 13:53
美股大行评级 | 最高700美元！大摩、瑞银等10家大行集体上调美光目标价；通用磨坊、梅西百货、SailPoint等遭多家大行下调目标价
今日重点评级关注：RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从32美元升至35美元；巴克莱：维持CytomX医疗"超配"评级，目标价从10美元升至16美元
03-20 15:53
RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35
RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $32 to $35.
03-19 22:04
